Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV
In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct. However, to the best of our knowledge there has been no reported cases of effect...
Main Authors: | Lili Wang, Jiyan Xu, Yu Kong, Ruiying Liang, Wei Li, Jinyao Li, Jun Lu, Dimiter S. Dimitrov, Fei Yu, Yanling Wu, Tianlei Ying |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-11-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4468/8/4/53 |
Similar Items
-
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
by: Marlena Surowka, et al.
Published: (2021-01-01) -
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
by: Stefania C. Carrara, et al.
Published: (2022-12-01) -
Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
by: Luigi Liguori, et al.
Published: (2022-11-01) -
Design and Production of Bispecific Antibodies
by: Qiong Wang, et al.
Published: (2019-08-01) -
A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein
by: Yingzhu Chen, et al.
Published: (2017-01-01)